scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rhea-AI Summary
scPharmaceuticals (SCPH) reported strong Q4 and full-year 2024 results, with Q4 FUROSCIX revenue reaching $12.2 million (up 99% YoY) and full-year revenue of $36.3 million (up 167% YoY). The company filled approximately 13,300 FUROSCIX doses in Q4 2024, a 23% increase from Q3.
Key highlights include FDA approval for FUROSCIX's expanded label to treat edema in chronic kidney disease patients, with launch planned for April 2025. The company reported about 3,800 unique prescribers through year-end 2024, showing 23% growth from Q3. The gross-to-net discount was 19% for Q4 and 16% for full-year 2024.
Financial position remains strong with $75.7 million in cash and cash equivalents as of December 31, 2024. However, the company reported a net loss of $18.8 million in Q4 and $85.1 million for the full year 2024.
Positive
- Q4 revenue grew 99% YoY to $12.2M, with full-year revenue up 167% to $36.3M
- FDA approval for expanded FUROSCIX indication to include CKD patients
- 23% QoQ growth in FUROSCIX doses filled (13,300 in Q4)
- 123% growth in Integrated Delivery Networks from Q3 2024
- Strong cash position of $75.7M as of December 2024
Negative
- Net loss increased to $85.1M in 2024 from $54.8M in 2023
- SG&A expenses increased 45% YoY to $77.6M in 2024
- Cost of product revenues increased significantly to $11.4M in 2024 from $3.8M in 2023
Insights
scPharmaceuticals' Q4 results demonstrate impressive commercial momentum with FUROSCIX revenue reaching
The recent FDA approval for FUROSCIX's expanded label to include chronic kidney disease patients represents a significant market opportunity expansion. With approximately 37 million Americans suffering from CKD, this opens a substantial new addressable market beyond the heart failure indication. The company's planned April 2025 formal launch for this indication is well-timed.
Despite the revenue growth, operating losses expanded to
The company maintained a relatively stable cash position of
The operational metrics are particularly encouraging: 13,300 FUROSCIX doses filled in Q4 (up
The FDA approval for FUROSCIX's chronic kidney disease indication represents a strategically significant expansion that aligns with current healthcare system priorities. Fluid overload management in CKD patients has traditionally relied on hospitalization or infusion center visits, creating substantial healthcare system costs and patient burden. FUROSCIX's at-home subcutaneous delivery model addresses this inefficiency directly.
The product's growing penetration into Integrated Delivery Networks (IDNs) is particularly noteworthy, with the
The upcoming 80mg/1mL Autoinjector development could be transformative from a healthcare economics perspective. The potential
With approximately 41,000 FUROSCIX doses filled in 2024 and accelerating quarterly growth rates, the product appears to be overcoming initial adoption hurdles typical for novel drug delivery systems. The expanding prescriber base (3,800 unique prescribers) indicates growing clinician comfort with subcutaneous furosemide as an alternative to traditional IV delivery.
The company's focus on CKD expansion shows recognition of healthcare system priorities around reducing hospitalizations in high-cost chronic disease populations. Nephrologists represent a more concentrated prescriber base than general cardiologists, potentially allowing for more efficient commercial targeting as this indication launches formally in April 2025.
scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of
Cash and cash equivalents of
U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease
scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET
BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (the “Company”), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
Business Update
- For the fourth quarter and full year ended December 31, 2024, scPharmaceuticals reports:
- Net FUROSCIX revenue of
$12.2 million and$36.3 million for the fourth quarter and full year 2024, respectively, compared to$6.1 million and$13.6 million for the same periods in 2023, up99% and167% respectively - Approximately 13,300 FUROSCIX doses filled in the fourth quarter of 2024, representing a
23% increase from the 10,800 doses filled in the third quarter of 2024 - Approximately 41,000 FUROSCIX doses filled in 2024
- Gross-to-net (GTN) discount of
19% and16% for the fourth quarter and full year 2024, respectively - Approximately 3,800 unique prescribers from launch through year end 2024, up approximately
23% from the end of the third quarter - Continued expansion into Integrated Delivery Networks (IDNs), with
123% growth from the third quarter of 2024
- Net FUROSCIX revenue of
- FUROSCIX Approved for Chronic Kidney Disease (CKD): On March 6, 2025, the FDA approved the sNDA to expand the FUROSCIX indication to include the treatment of edema in patients with chronic kidney disease. scPharmaceuticals anticipates formally launching the new indication in April 2025, and has completed key pre-launch initiatives, including key opinion leader engagement, comprehensive market research, and commercial readiness activities.
- 80mg/1mL FUROSCIX Autoinjector: scPharmaceuticals continues to advance the SCP-111 Autoinjector 80mg/1mL FUROSCIX program and is targeting the supplemental New Drug Application (sNDA) submission mid-year. If approved, the Autoinjector will potentially give physicians another treatment option for patients and has the potential to reduce costs associated with FUROSCIX by approximately
70% .
“We were pleased to receive approval of FUROSCIX in CKD from the FDA, which we believe is a critical market opportunity for scPharmaceuticals and a core component of the long-term franchise expansion plans for FUROSCIX. The nephrologists in our preliminary call points understand where FUROSCIX fits into the treatment paradigm, and the benefits it can bring to these patients when they experience fluid overload,” stated John Tucker, President, and Chief Executive Officer of scPharmaceuticals. “As we focus on 2025, we remain encouraged by the significant tailwinds, including scPharmaceuticals’ expanded field sales force, the indication expansion into the CKD market, and the full year impact of the Medicare Part D redesign.”
Fourth Quarter and Full-Year 2024 Financial Results
Product revenues were
Cost of product revenues were
Research and development (R&D) expenses were
Selling, general and administrative (SG&A) expenses were
scPharmaceuticals reported a net loss of
scPharmaceuticals ended 2024 with
As of December 31, 2024, scPharmaceuticals’ total shares outstanding was 50,095,689.
Conference call and webcast information
scPharmaceuticals’ management will host a conference call and webcast to review the Company’s fourth quarter and full-year 2024 results today, Wednesday, March 19, at 4:30 p.m. ET.
A link to the live webcast can be found here.
A link to the live conference call can be found here.
Following the live webcast, a replay of the event will be archived on scPharmaceuticals’ website for one year.
INDICATION
FUROSCIX® (furosemide injection), 80 mg/10 mL for subcutaneous use is indicated for the treatment of edema (i.e., congestion, fluid overload, or hypervolemia) in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome.
IMPORTANT SAFETY INFORMATION
FUROSCIX is contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives.
Furosemide may cause fluid, electrolyte, and metabolic abnormalities, particularly in patients receiving higher doses, patients with inadequate oral electrolyte intake, and in elderly patients. Serum electrolytes, CO2, BUN, creatinine, glucose, and uric acid should be monitored frequently during furosemide therapy.
Excessive diuresis may cause dehydration and blood volume reduction with circulatory collapse and possibly vascular thrombosis and embolism, particularly in elderly patients.
Furosemide can cause dehydration and azotemia. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.
Cases of tinnitus and reversible or irreversible hearing impairment and deafness have been reported with furosemide. Reports usually indicate that furosemide ototoxicity is associated with rapid injection, severe renal impairment, the use of higher than recommended doses, hypoproteinemia or concomitant therapy with aminoglycoside antibiotics, ethacrynic acid, or other ototoxic drugs.
In patients with severe symptoms of urinary retention (because of bladder emptying disorders, prostatic hyperplasia, urethral narrowing), the administration of furosemide can cause acute urinary retention related to increased production and retention of urine. These patients require careful monitoring, especially during the initial stages of treatment.
Contact with water or other fluids and certain patient movements during treatment may cause the On-body Infusor to prematurely terminate infusion. Ensure patients can detect and respond to alarms.
The most common adverse reactions with FUROSCIX administration in clinical trials were site and skin reactions including erythema, bruising, edema, and injection site pain.
Please see the full Prescribing Information (www.furoscix.com/prescribing-information.pdf) and Instructions for Use (www.furoscix.com/instructions-for-use.pdf).
About scPharmaceuticals
At scPharmaceuticals, we are powered by passion, driven by patient care. Our Mission is focused on advancing cardiorenal care through innovative, integrated treatments that address unmet patient needs.
Our goal is to become the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches. scPharmaceuticals is expanding its reach, offering integrated therapies and products that address diverse healthcare needs and potentially improve the lives of our patients. scPharmaceuticals is headquartered in Burlington, MA. For more information, please visit www.scPharmaceuticals.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the development and commercialization of products, such as the autoinjector, and its potential to increase patient care and the treatment of fluid at home; the anticipated submission of a sNDA for 80mg/1mL FUROSCIX Autoinjector in mid-year 2025; our commercial strategy for FUROSCIX and anticipated sales; the expected GTN discount for 2025; the impact of our ongoing expansion efforts including our expanded sales force; anticipated additional growth with the implementation of the Medicare redesign; the launch of FUROSCIX to treat CKD; our participation in upcoming events and presentations; and the timing of any of the foregoing. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, our dependence on the commercial success of FUROSCIX and, if approved, our other product candidates; risks related to the receipt of regulatory approval for our product candidates; risks related to our ability to manufacture, or the ability of third parties to deliver, sufficient product for commercialization of FUROSCIX or any of our product candidates, if approved; risks related to our history of operating losses, we have a history of significant operating losses and expect to incur significant and increasing losses for the foreseeable future; we may never achieve or maintain profitability; we may need additional funding and may be unable to raise capital when needed, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts; the terms of our credit facility and revenue participation financing facility place restrictions on our operating and financial flexibility, and we may not have cash available to us in an amount sufficient to enable us to make interest or principal payments on our indebtedness when due; clinical and preclinical development involves a lengthy and expensive process with an uncertain outcome, and any difficulties or delays in the commencement or completion, or the termination or the potential for the results from any clinical trials to support submission of sNDAs or comparable regulatory applications; and the risk that global economic factors and uncertainties will impact the Company’s operations. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the sections entitled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, on file with the Securities and Exchange Commission, available at the Securities and Exchange Commission’s website at www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in the Company’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
Katherine Miranda
scPharmaceuticals Inc., 781-301-6869
kmiranda@scpharma.com
Investors:
Nick Colangelo
Gilmartin Group, 339-225-1047
Nick@GilmartinIR.com
| scPharmaceuticals Inc. | ||||||||||||||||
| Consolidated Statements of Operations | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| THREE MONTHS ENDED DECEMBER 31, | YEAR ENDED DECEMBER 31, | |||||||||||||||
| 2023 | 2024 | 2023 | 2024 | |||||||||||||
| Product revenues, net | $ | 6,096 | $ | 12,150 | $ | 13,593 | $ | 36,332 | ||||||||
| Operating expenses: | ||||||||||||||||
| Cost of product revenues | $ | 1,773 | $ | 3,965 | $ | 3,811 | $ | 11,361 | ||||||||
| Research and development | 3,338 | 3,154 | 11,809 | 12,098 | ||||||||||||
| Selling, general and administrative | 16,242 | 21,374 | 53,369 | 77,649 | ||||||||||||
| Total operating expenses | 21,353 | 28,493 | 68,989 | 101,108 | ||||||||||||
| Loss from operations | (15,257 | ) | (16,343 | ) | (55,396 | ) | (64,776 | ) | ||||||||
| Loss on extinguishment of debt | - | - | - | (13,032 | ) | |||||||||||
| Change in fair value of term loan | - | (251 | ) | - | (3,205 | ) | ||||||||||
| Change in fair value of revenue purchase and sale liability | - | (1,812 | ) | - | (3,642 | ) | ||||||||||
| Other income | 2,412 | 46 | 3,605 | 3,633 | ||||||||||||
| Interest income | 1,125 | 1,000 | 5,104 | 3,444 | ||||||||||||
| Interest expense | (2,092 | ) | (1,485 | ) | (8,123 | ) | (7,570 | ) | ||||||||
| Net loss | $ | (13,812 | ) | $ | (18,845 | ) | $ | (54,810 | ) | $ | (85,148 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.35 | ) | $ | (0.35 | ) | $ | (1.42 | ) | $ | (1.91 | ) | ||||
| Weighted—average common shares outstanding, basic and diluted | 38,786,956 | 53,462,646 | 38,513,747 | 44,519,669 | ||||||||||||
| scPharmaceuticals Inc. | ||||||||
| Consolidated Balance Sheet Data | ||||||||
| (in thousands) | AS OF DECEMBER 31, | |||||||
| 2023 | 2024 | |||||||
| Cash, cash equivalents and investments | $ | 76,013 | $ | 75,655 | ||||
| Working capital | 79,804 | 90,973 | ||||||
| Total assets | 94,479 | 107,519 | ||||||
| Term loan | 38,811 | 51,350 | ||||||
| Revenue purchase and sale liability | — | 26,869 | ||||||
| Accumulated deficit | (281,346 | ) | (366,494 | ) | ||||
| Total stockholders’ equity | 37,218 | 13,320 | ||||||
FAQ
What was SCPH's revenue growth for FUROSCIX in Q4 2024?
When will SCPH launch FUROSCIX for chronic kidney disease patients?
How many unique FUROSCIX prescribers did SCPH have by end of 2024?
What was SCPH's cash position at the end of 2024?
What is the potential cost reduction with SCPH's new 80mg/1mL FUROSCIX Autoinjector?
